Showing 3151-3160 of 4063 results for "".
- CoFi Reaches New Milestone: 10,000 Vision Providers are Now Active on CoFi’s Multi-Party Payment Platformhttps://modernod.com/news/cofi-reaches-new-milestone-10000-vision-providers-are-now-active-on-cofis-multi-party-payment-platform/2482648/CoFi announced it has reached a new milestone of more than 10,000 ophthalmologists and optometrists active on the CoFi platform. Since CoFi’s commercial launch in the summer of 2021, the company has been growing rapidly, with nearly 200 new vision practices joining the platform each month i
- Applications Being Accepted for the New AAOF and Meta Reality Labs Research $1.5 Million Open-Science Myopia Granthttps://modernod.com/news/applications-being-accepted-for-the-new-aaof-and-meta-reality-labs-research-15-million-open-science-myopia-grant/2482636/The American Academy of Optometry Foundation (AAOF) and Meta Reality Labs Research (RLR) have launched a new grant opportunity aimed at advancing research in the field of myopia and its connection to visual experience. The 2025 Myopia Research Grant will provide three award
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- EMA Endorses Macustar's Work on Early AMD Clinical Trialshttps://modernod.com/news/ema-endorses-macustars-work-on-early-amd-clinical-trials/2482631/The European Medicines Agency (EMA) has issued its third 'Letter of Support' to the Macustar consortium, a European public-private partnership focused on advancing clinical trial methodologies for early-stage age-related macular degeneration (AMD). This endorsement follows the consortium&
- Heidelberg Hosts First International Glaucoma Symposiumhttps://modernod.com/news/heidelberg-hosts-first-international-glaucoma-symposium/2482628/The first International Glaucoma Symposium will be held by Heidelberg Engineering in conjunction with Mainz University on February 1, 2025. Bringing together specialists from around the world, the symposium calls for AI to be fully implemented as an increasing number of glaucoma and dia
- AbbVie and Regenxbio Announce Updates on the ABBV-RGX-314 Clinical Program in DR and Wet AMDhttps://modernod.com/news/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-in-dr-and-wet-amd/2482618/AbbVie and Regenxbio announced updates to the ABBV-RGX-314 gene therapy clinical program. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. The co
- Rayner Introduces Redesigned RayTrace for Quicker and Clearer IOL Calculationshttps://modernod.com/news/rayner-introduces-redesigned-raytrace-for-quicker-and-clearer-iol-calculations/2482604/Rayner announced the launch of its redesigned online premium IOL calculator, RayTrace. One of the first online IOL calculation tools, RayTrace has been used by surgeons globally since 2008 for the accuracy of its premium IOL (toric, multifocal and supplementary) calculations,
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Scientists Explore Regrowth of Optic Nerves as Potential Treatment for Glaucomahttps://modernod.com/news/scientists-explore-regrowth-of-optic-nerves-as-potential-treatment-for-glaucoma/2482591/University of Connecticut scientists have published a report in the September issue of Experimental Neurology, showing injured optic nerves can regrow towards the brain if treated properly. Blunt trauma to t
- Sepul Bio Announces First Patient Dosed in Trial Using Ultevursen for RPhttps://modernod.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/Sepul Bio announced the first person has been dosed for the LUNA clinical study, a phase 2b trial using ultevursen for USH2A-associated retinitis pigmentosa (RP). USH2A, or Usher Syndrome type 2a, is the most common cause of autosomal recessive retinitis pigmentosa that affec